Nektar Therapeutics Net Fee Amt
Nektar Therapeutics (NKTR) had Net Fee Amt of $31.01 thousand as of 2026-08-11, per its S-8 filed 2026-08-14.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-14
- 2026-08-11: Net Fee Amt $31.01K.
- 2026-05-08: Net Fee Amt $20.71K.
- 2026-04-22: Net Fee Amt $51.61K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-11 | $31.01K S-8 · filed 2026-08-14 |
| 2026-05-08 | $20.71K 424B5 · filed 2026-05-08 |
| 2026-04-22 | $51.61K 424B5 · filed 2026-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |